High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

doi:10.1182/blood.2021012206

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

科研成果: 期刊稿件 › 文章 › 同行评审

源语言	英语
页（从-至）	2337-2346
页数	10
期刊	Blood
卷	138
期	23
DOI	https://doi.org/10.1182/blood.2021012206
出版状态	已出版 - 12月 9 2021
已对外发布	是

!!!ASJC Scopus Subject Areas

生物化学
免疫学
血液学
细胞生物学

访问文件

10.1182/blood.2021012206

其它文件与链接

引用此

@article{cc99f8a1af9d4619a8228fcddd706061,

title = "High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial",

note = "Publisher Copyright: {\textcopyright} 2021 American Society of Hematology",

year = "2021",

month = dec,

day = "9",

doi = "10.1182/blood.2021012206",

language = "English",

volume = "138",

pages = "2337--2346",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "23",

}

TY - JOUR

T1 - High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD

T2 - results of the COG AAML1531 trial

PY - 2021/12/9

Y1 - 2021/12/9

UR - http://www.scopus.com/inward/record.url?scp=85120750215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120750215&partnerID=8YFLogxK

U2 - 10.1182/blood.2021012206

DO - 10.1182/blood.2021012206

M3 - Article

C2 - 34320162

AN - SCOPUS:85120750215

SN - 0006-4971

VL - 138

SP - 2337

EP - 2346

JO - Blood

JF - Blood

IS - 23

ER -

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

!!!ASJC Scopus Subject Areas

访问文件

其它文件与链接

指纹

引用此